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The involvement of Toll-like receptor 4 (TLR4) in im-
munity against human herpesviruses has not been
previously demonstrated. We show that infection of
endothelial cells with Kaposi sarcoma herpesvirus
(KSHV), a human oncogenic virus, leads to rapid sup-
pression of TLR4 expression. This is a mechanism of
immune escape as TLR4 mediates innate immunity
against KSHV. In vitro, cells lacking TLR4 are more
susceptible to KSHV infection, whereas activation
of TLR4 protects cells from infection. In vivo, HIV-1-
infected individuals carrying a mutant TLR4 allele
appear more likely to have multicentric Castleman’s
disease, a lymphoproliferation associated with en-
hanced KSHV replication. ERK activation by KSHV
structural proteins and the KSHV-encoded vGPCR
plays a key role in the TLR4 downregulation, whereas
the KSHV vIRF1 also contributes to this effect. Our
findings reveal a role for TLR4 in innate immunity
against herpesviruses and suggest the potential
use of TLR4 agonists for the treatment of KSHV-
related neoplasms.
INTRODUCTION
Toll-like receptors (TLR) are a family of membrane pattern
recognition receptors recognizing highly conserved metabolic
products of invading pathogens, termed pathogen-associated
molecular patterns (PAMPs). TLRs are type I glycoproteins con-
sisting of an extracellular PAMP recognition domain and a cyto-
plasmic Toll/interleukin-1 receptor homology signaling domain.
Effective pathogen recognition can be achieved through a small
number of TLRs (ten in humans). As PAMPs are indispensable
for the invading pathogen, no escape mutants can evolve.
Upon PAMP recognition, TLR activation leads to the initiation of
an innate inflammatory response through activation of the nuclear
factor kB (NF-kB), mitogen-activated protein kinase (MAPK), and
interferon regulatory factor (IRF) pathways (Akira et al., 2006;
Janeway and Medzhitov, 2002). In parallel, a complex regulatory
network of TLR signaling exists to regulate this innate response
(Liew et al., 2005).470 Cell Host & Microbe 4, 470–483, November 13, 2008 ª2008 ElsThe first characterized mammalian TLR was the human TLR4
(Medzhitov et al., 1997). It is expressed by cells of the immune
system, such as dendritic cells, macrophages, and B lympho-
cytes, but also by endothelial cells. TLR4 acts in combination
with serum or membrane CD14 and the adaptor protein MD2
as the receptor of bacterial lipopolysaccharide (LPS), playing
a key role in innate responses against Gram-negative bacteria
(Akira et al., 2006). TLR4 also recognizes other ligands such as
the glycoprotein F of respiratory syncytia virus (RSV) (Kurt-Jones
et al., 2000), as well as endogenous proteins including heat shock
proteins, fibrinogen, and high-mobility-group box 1 (Apetoh et al.,
2007; Marshak-Rothstein, 2006). Based on its exogenous
ligands, TLR4 is generally associated with responses to Gram-
negative bacteria and RSV. Notably, two single nucleotide poly-
morphisms (SNP) in the human TLR4 gene (Asp299Gly resulting
from an A/G substitution, rs4986790, and Ile399Thr resulting from
a C/T substitution, rs4986791) have been associated with sever-
ity of RSV-associated bronchiolitis and Gram-negative sepsis
(Schroder and Schumann, 2005). Activation of TLR4 by a mouse
RNA virus (mouse mammary tumor virus; MMTV) is thought to
lead to subversion of the immune response (Burzyn et al.,
2004). Furthermore, TLR4 has been implicated in responses
against hepatitis C virus (Machida et al., 2006) and in mouse
models of hepatitis B virus infection (Isogawa et al., 2005),
whereas TLR4 activation by LPS in mouse macrophages inhibits
replication of murine herpesvirus 68 (MHV68) by induction of an
IRF3- and IRF7-mediated response (Doyle et al., 2002). However,
a role for TLR4 in responses against human herpesviruses has not
previously been demonstrated.
Kaposi sarcoma-associated herpesvirus (KSHV; also known
as human herpesvirus 8) is an oncogenic human g-herpesvirus
associated with the development of Kaposi sarcoma (KS), a neo-
plasm of lymphatic endothelial-type cells (Wang et al., 2004), and
certain lymphoproliferations, such as multicentric Castleman’s
disease (MCD) (Boshoff and Weiss, 2002). As a herpesvirus,
KSHV establishes life-long infection in its host. In latently infected
cells, only a fraction of viral genes are expressed, maintaining the
viral episome, and providing a proliferative and immune escape
advantage to infected cells. The viral genes expressed during la-
tency include the latency-associated nuclear antigen 1 (LANA-1),
viral cyclin, and viral FLICE inhibitory protein (vFLIP; reviewed in
Moore and Chang [2003]). When infected cells enter a productive
(lytic) program of gene expression, most of the viral genes are
expressed, virions are formed, and new cells are recruited to beevier Inc.
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receptor (vGPCR), which is a multifunctional viral oncogene ho-
mologous to the human IL8 receptor, and the viral IRF1 (vIRF1),
which inhibits interferon signaling (reviewed in Cannon [2007]
and Moore and Chang [2003]). As herpesviruses have evolved
to establish persistent infection (and therefore an immunological
equilibrium with their host), most of the viral mechanisms of im-
mune evasion occur during lytic and primary infection (Coscoy,
2007; Moore and Chang, 2003). This equilibrium is disturbed in
immunosuppressed individuals, resulting in uncontrolled prolifer-
ation of infected cells and occasional development of cancer.
Thus, the incidence of KSHV-related malignancies is dramatically
increased among transplant recipients during iatrogenic immu-
nosuppression and in HIV-1-infected individuals, where KS is
the most common AIDS-related cancer (Boshoff and Weiss,
2002).
Although several aspects of the KSHV-specific immune re-
sponses and viral mechanisms of immune escape have been
studied (Coscoy, 2007), the role and regulation of TLRs in innate
immunity against KSHV remain unknown. Here we show that
TLR4 mRNA levels and protein expression are significantly down-
regulated upon primary KSHV infection of human lymphatic
endothelial cells (LEC). Using macrophages from TLR4-knockout
mice, siRNA-mediated silencing of TLR4 in human LEC, and
activation of endogenous TLR4 signaling, we demonstrate that
TLR4 mediates an innate immune response against KSHV. The
in vivo relevance of these findings is demonstrated by the higher
incidence of the Asp299Gly TLR4 SNP among HIV-1-infected
individuals with MCD, a KSHV-driven lymphoproliferation associ-
ated with high KSHV load. Consistently, primary LEC carrying this
TLR4 allele are more susceptible to KSHV infection than LEC
carrying the wild-type TLR4 gene. Furthermore, we demonstrate
that KSHV suppresses TLR4 through activation of the extracellu-
lar signal-regulated kinase (ERK) MAPK pathway during viral
binding (viral gene expression-independent mechanism), and
by way of vIRF1 and ERK activation by vGPCR (viral gene expres-
sion-dependent mechanism).
RESULTS
KSHV Infection of Lymphatic Endothelial Cells Leads
to Suppression of TLR4 Expression
We have previously determined the immune transcriptional
signature of KSHV-infected LEC (KLEC) using gene expression
microarray (GEM) profiling (Lagos et al., 2007). We analyzed
these data focusing on TLRs and observed a significant downre-
gulation of TLR4 levels (false discovery rate threshold q < 0.005;
Figure 1A). The only other significant effects of infection on TLR
expression were an upregulation of TLR2 and a downregulation
of TLR3. However, the normalized signal for basal TLR3 mRNA
levels in LEC was low (Figure S1A), suggesting that TLR3 is not
significantly expressed in these cells. Thus, we considered only
TLR4 as significantly downregulated after infection. TLR4 acts
as the functional LPS receptor, in the presence of soluble CD14
(sCD14), on dermal microvasculature, umbilical vein, and lym-
phatic endothelial cells (Faure et al., 2000; Pegu et al., 2008;
Pugin et al., 1993). In our system, we confirmed that TLR4 is ex-
pressed and functional in response to LPS (through upregulation
of ICAM-1) in primary LEC (Figures S1B and S1C). Following this,Cell Hostwe validated our GEM data by quantitative reverse transcriptase
polymerase chain reaction (qRTPCR) and confirmed that TLR4
mRNA levels are downregulated after KSHV infection, whereas
mRNA levels of TLR9, the TLR typically associated with re-
sponses to DNA viruses (Guggemoos et al., 2008; Muller et al.,
2008), were not affected by KSHV (Figure 1B). The TLR4 mRNA
decrease led to significant downregulation of TLR4 surface ex-
pression (reducing TLR4 geomean fluorescence to levels similar
to isotype control; Figures 1C and S1D). Notably, TLR4 mRNA
levels were downregulated as early as 6 hr postinfection (p.i.)
and the effect persisted up to 72 hr p.i. (Figure 1D). Early TLR4
downregulation (6 hr p.i.) also occurred when LEC were exposed
to UV-inactivated KSHV (Figure 1E) inferring that structural KSHV
proteins contribute to this effect. However, at later time points
(72 hr p.i.), TLR4 levels significantly increased in LEC exposed
to UV-inactivated KSHV compared to KLEC (Figure 1E). Further-
more, TLR4 downregulation correlated with number of KSHV-
infected cells (Figure 1F). These findings indicated that KSHV
employed mechanisms independent of and driven by viral gene
expression to downregulate TLR4. To exclude any confounding
effects of contaminating traces of LPS on TLR4 expression, we
showed that LPS did not affect basal TLR4 expression in LEC
(Figure S1E) and that the TLR4 downregulation still occurred
when the infection was performed in the presence of poly-
myxin-B (an inhibitor of the LPS-TLR4 interaction; Figure S1F).
Next we assessed the functional relevance of the TLR4 down-
regulation by KSHV. One of the first events upon TLR4 activation
involves the phosphorylation, ubiquitination, and degradation of
IRAK1 (Gottipati et al., 2008). In LEC, we observed transient
phosphorylation of IRAK1 within 5–10 min of stimulation with LPS
followed by protein degradation. IRAK1 activation after LPS
stimulation was significantly impaired in KLEC (72 hr p.i.; Fig-
ure 1G). Similarly, transcriptional induction and secretion of
TNF-a after stimulation with LPS (one of the endpoints of the
TLR4 signaling cascade) was significantly impaired in KLEC
(72 hr p.i.; Figure 1H).
TLR4 Mediates an Innate Immune Response
Against KSHV
The rapid TLR4 downregulation during primary KSHV infection of
LEC suggested that TLR4 might play a role in the innate re-
sponse against this virus. Although KSHV does not infect mice
with functional T lymphocytes, it has been shown using NOD/
SCID mice that macrophages are one of the viral cellular targets
in vivo (Parsons et al., 2006). Therefore, we first tested the role of
TLR4 in the response against KSHV using peritoneal macro-
phages from C57BL10/ScNJ mice, which lack the Tlr4 gene,
and wild-type controls (C57BL10/ScSnJ). KSHV infection of
macrophages from the Tlr4 knockout mice led to a 2- to 3-fold
higher viral gene expression compared to wild-type controls
(Figure 2A).
As differences in the activation of mouse and human TLR4
genes have been reported (Kawasaki et al., 2001) and KSHV is
considered to be species restricted, we next tested the role of
TLR4 in the innate response during primary infection of human
LEC. Similar to the data we obtained using macrophages from
Tlr4 knockout mice, infection of human LEC after siRNA-medi-
ated TLR4 silencing resulted in higher viral gene expression
(Figure 2B). This correlated with an impaired innate response as& Microbe 4, 470–483, November 13, 2008 ª2008 Elsevier Inc. 471
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TLR4 Role and Regulation in KSHV InfectionFigure 1. KSHV Suppresses TLR4 Expression
(A) Heatmap of TLR expression in LEC and KSHV-infected LEC (KLEC; 72 hr p.i.), based on GEM profiling. Rows correspond to TLR probe sets. Red and blue
denote high and low expression respectively, the color scale indicating units of standard deviation from the mean.
(B) TLR4 and TLR9 mRNA levels in LEC (gray bars) and KLEC (black bars) 72 hr p.i.
(C) Surface TLR4 expression in LEC and GFP-expressing KLEC (72 hr p.i.).
(D) Time course of TLR4 mRNA levels in LEC (gray bars) and KLEC (black bars). For each time point, mRNA levels are normalized to LEC TLR4 mRNA levels.
(E) TLR4 mRNA levels in LEC infected with UV-inactivated KSHV normalized to KLEC TLR4 mRNA at 6 hr and 72 hr p.i. P value between UV-inactivated samples
and KLEC is shown.
(F) TLR4 mRNA levels in relation to percentage of GFP-expressing KLEC (24 hr p.i.). Values normalized to LEC and P values shown.472 Cell Host & Microbe 4, 470–483, November 13, 2008 ª2008 Elsevier Inc.
Cell Host & Microbe
TLR4 Role and Regulation in KSHV InfectionsiRNA-mediated TLR4 silencing also caused impaired induction
of TNF-a, IL1-b, IL-6, and IFN-b after KSHV infection of LEC (Fig-
ure 2C). Together, these results demonstrated that TLR4 contrib-
utes to the innate response during primary KSHV infection. This
antiviral activity is likely to be the result of TLR4 activation by a viral
envelope glycoprotein, as exposure of LEC to UV-inactivated
KSHV also led to a TLR4-dependent induction of TNF-a, IL1-b,
IL-6, and IFN-b (Figure 2D).
Next, we investigated whether it was possible to inhibit KSHV
infection by activating TLR4 before exposure to the virus. Activa-
tion of TLR4 signaling with LPS resulted in decreased number of
infected cells (Figure 3A), a reduction in the number of viral
genome copies per infected cell (Figure 3B), and lower latent,
early lytic, and late lytic viral gene expression (Figure 3C). To
exclude nonspecific effects of LPS on KSHV infection, we
showed that LPS treatment did not affect KSHV infection of mac-
rophages from C57BL10/ScNJ Tlr4/ mice or human 293T cells
(Figure S2), which do not express TLR4 and do not respond to
LPS. Furthermore, we showed that TLR4 activation by LPS
resulted in IFN-b induction (Figure 3D), and that inhibition of
type I interferon activity reversed the protective effect of TLR4
activation against KSHV infection (Figure 3E).
Increased Incidence of the Asp299Gly TLR4 SNP among
HIV-1-Infected Individuals with MCD
Based on the above results we investigated whether SNPs asso-
ciated with the deregulation of TLR4 activity (Ferwerda et al.,
2007; Tulic et al., 2007) result in higher KSHV load in vitro and
in vivo and therefore development of KSHV-associated neo-
plasms. First, we compared primary human LEC carrying a
heterozygous Asp299Gly mutant allele with wild-type TLR4
LEC. In agreement with previous observations with transfected
wild-type and mutant TLR4 constructs (Tulic et al., 2007), we
observed that LEC-TLR4A/A (wild-type) express higher levels of
surface TLR4 than LEC-TLR4A/G (mutant), whereas TLR4 mRNA
levels did not differ between the two cell types. The two cell types
were also matched for TLR9 mRNA levels (Figure 4A). To deter-
mine the TLR4 activity in the wild-type and mutant cells, we
examined their response to LPS stimulation. In agreement with
previous findings, we observed that stimulation of LEC-TLR4A/G
with LPS resulted in significantly higher induction of proinflamma-
tory cytokine transcription compared to wild-type LEC. Notably,
in contrast to the inflammatory gene profile, our data also
suggested that LEC-TLR4A/G produced less IFN-b upon TLR4
stimulation with LPS (Figure 4B). As we showed that KSHV
activates TLR4 (Figure 2B), we speculated that the combination
of an impaired interferon and an enhanced inflammatory
TLR4-mediated response could make the mutant cells more
susceptible to KSHV infection. Indeed, we showed that KSHV
infection of LEC-TLRA/G was significantly more efficient com-
pared to LEC-TLR4A/A (Figures 4C and 4D).
The above results indicated that cells carrying TLR4 SNP may
be more susceptible to KSHV infection. To assess this hypothe-Cell Hostsis in vivo, we determined the frequency of two TLR4 SNPs in a
cohort of 109 HIV-1-infected individuals. In this cohort, 43 indi-
viduals were diagnosed with KSHV-associated cancers (23 KS,
9 KS and MCD, 11 MCD), and 66 HIV-1-infected controls had
non-KSHV-associated cancers or no cancer (Table S1). The
frequencies of the Asp299Gly and Ile399Thr polymorphisms in
the entire cohort were 12.8% and 4.6%, respectively. All individ-
uals were heterozygous for the polymorphisms and the Ile399Thr
SNP cosegregated with the Asp299Gly mutation (Figure 5A).
We observed a statistically significant higher frequency of the
Asp299Gly SNP among individuals with MCD in comparison
with non-KSHV cancer controls (30% versus 10.6%, p = 0.044;
Figures 5A and 5B) and in comparison to individuals with only
KS (30% versus 4.3%, p = 0.026). Furthermore, our data showed
that HIV-1-infected individuals with the Asp299Gly SNP were
more likely to have MCD when compared to individuals carrying
the wild-type TLR4 allele (odds ratio 4.34, 95% confidence inter-
val 1.3–14.4, p = 0.021). We also confirmed in this cohort that
MCD (with or without KS) is associated with higher plasma
KSHV load compared to KS (Figure 5C; KSHV load is shown at
time of diagnosis). These findings infer that HIV-1/KSHV-co-
infected individuals with the Asp299Gly TLR4 SNP are more
likely to have MCD and are consistent with our in vitro results
demonstrating the role of TLR4 in immunity against KSHV.
vGPCR and vIRF1 Contribute to the TLR4
Downregulation by KSHV
We have shown here that TLR4 mediates an antiviral response
and is significantly downregulated upon KSHV infection. We
therefore investigated the mechanism employed by KSHV to
suppress TLR4. We determined TLR4 expression in LEC
expressing 25 individual KSHV genes using a lentiviral gene de-
livery vector as previously reported (Lagos et al., 2007; Vart et al.,
2007) to achieve efficient and stable viral gene expression in
LEC. An initial screen revealed that expression of the KSHV
vGPCR or vIRF1 caused a decrease in TLR4 mRNA levels,
whereas no viral genes resulted in significant upregulation of
TLR4 (Table S2). These findings were first confirmed for vIRF1
at the mRNA and protein levels (Figures 6A and S3), showing
a decrease of TLR4 expression by vIRF1 in a dose-dependent
manner. Furthermore, we showed that vIRF1 is primarily respon-
sible for the TLR4 downregulation, but also that vGPCR contrib-
utes to suppression of TLR4 expression as coexpression of
vIRF1 and vGPCR in LEC led to an additive effect on TLR4
expression (Figure 6B). In these experiments, the viral genes
were expressed at levels where no cytopathic effects were
observed (a maximum of 10 copies/cell for vGPCR, 50 copies/
cell for vIRF1 when expressed alone, and 20 copies/cell when
expressed with vGPCR). Notably, at these expression levels,
vIRF1 and vGPCR resulted in a decrease in TLR4 protein expres-
sion comparable to that observed in KLEC (72 hr p.i.), although
the TLR4 mRNA downregulation was more pronounced in
KLEC (Figures 1B, 1C, and 6B). We have previously shown(G) Levels of phosphorylated and total IRAK1 (p-IRAK1 and t-IRAK1, respectively) following stimulation of LEC and KLEC (72 hr p.i.) with 100ng/ml LPS/1 mg/ml
sCD14 for the indicated time. GAPDH levels are shown as loading controls. Note that the increase of the t-IRAK1 signal in LEC following LPS stimulation
represents an increase in the activated form of the protein rather than an increase in the total protein levels (Hatao et al., 2004).
(H) Levels of secreted TNF-a following stimulation of LEC (gray bars) and KLEC (black bars; 72 hr p.i.) with LPS/sCD14 for 6 hr and 24 hr. For (B)–(D) and (H),
P values between KLEC and LEC, samples are shown. In all panels, error bars represent standard deviation.& Microbe 4, 470–483, November 13, 2008 ª2008 Elsevier Inc. 473
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TLR4 Role and Regulation in KSHV InfectionFigure 2. Increased Susceptibility of Cells Lacking TLR4 to KSHV Infection
(A) mRNA levels of KSHV-encoded LANA-1 and ORF50 transcripts after KSHV infection (48 hr p.i.) of peritoneal macrophages from C57BL10/ScSnJ mice
(wild-type, white bars) and C57BL10/ScNJ mice (Tlr4/, gray bars). Levels normalized to average gene expression in KSHV-infected C57BL10/ScSnJ macro-
phages. P values indicate statistical significance of changes between C57BL10/ScNJ and C57BL10/ScSnJ macrophages.
(B) LANA-1 mRNA levels (white bars) in KLEC (48 hr p.i.). LEC were transfected with nontargeting siRNA (KLEC scramble) or TLR4-targeting siRNA (KLEC-siTLR4)
48 hr before KSHV infection. TLR4 surface expression (histograms; TLR4 geometrical mean fluorescence shown) and mRNA levels (black bars) were determined
48 hr post siRNA transfection. mRNA levels are normalized to KLEC-scramble levels.
(C) TNF-a, IL1-b, IL-6, and IFN-bmRNA levels 6 hr after KSHV infection of KLEC scramble (black bars) or KLEC-siTLR4 (gray bars). Levels are normalized to KLEC
scramble.
(D) As in (C), but after exposure of LEC to UV-inactivated KSHV. In (B)–(D), P values indicate statistical significance of changes between mRNA levels in KLEC
scramble and KLEC-siTLR4. In all panels, error bars represent standard deviation.474 Cell Host & Microbe 4, 470–483, November 13, 2008 ª2008 Elsevier Inc.
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TLR4 Role and Regulation in KSHV InfectionFigure 3. TLR4 Activation by LPS Protects
LEC from KSHV Infection
(A) Percentage of GFP-expressing cells in KLEC,
KLEC pretreated with sCD14 (1 mg/ml), and
KLEC pretreated with sCD14 (1 mg/ml) and LPS
(100 ng/ml).
(B) Average number of KSHV genomes per
GFP-expressing cell. Cells were pretreated as
described in (A).
(C) mRNA levels of KSHV latent, immediate lytic,
and late lytic genes (LANA, ORF50, and ORF26,
respectively) in KLEC pretreated with sCD14
(gray bars) or sCD14 and LPS (black). Levels are
normalized to sCD14 pretreated KLEC. In (A)–(C),
P values between KLEC pretreated with sDC14
and sCD14/LPS are shown, and experiments are
performed 72 hr p.i.
(D) IFN-b expression in LEC treated with PBS
(black bars) or 1 mg/ml sCD14 (gray bars) and vary-
ing amounts of LPS (x axis) for 6 hr. Ct values
(y axis) indicate cycle number when PCR products
become detectable. Samples are normalized for
GAPDH Ct. P values between PBS/LPS- and
sCD14/LPS-treated LEC for each LPS concentra-
tion are shown.
(E) ORF50 mRNA levels in KLEC and in KLEC pre-
treated with sCD14 and LPS or IFN-b (1000U/ml) in
the presence of an IFNaRII neutralizing antibody
(white bars) or an isotype control (gray bars).
IFN-b treatment was used to assess the neutraliz-
ing efficiency of the antibody. P values indicate
significant changes compared with to KLEC
control. In all panels, error bars represent standard
deviation.that both vIRF1 and vGPCR are expressed in KLEC at 72 hr p.i.
(Lagos et al., 2007; Vart et al., 2007).
To confirm that the TLR4 downregulation by vIRF1 and vGPCR
was functionally relevant, we tested whether these genes af-
fected response to LPS stimulation in LEC. We found that similar
to KLEC, LEC expressing vIRF1 and vGPCR displayed impaired
TNF-a induction after TLR4 activation, whereas response to
TLR9 stimulation was similar between these cells and controls
(Figure 6C), excluding that the observed hyporesponsiveness
to LPS was due to inhibition of TLR signaling by these viral genes
at a different level downstream of TLR4.
The Role of the ERK/MAPK Pathway in TLR4 Regulation
by KSHV in Endothelial Cells
The KSHV-encoded vIRF1 has been shown to inhibit IRF-driven
transcription (Coscoy, 2007; Moore and Chang, 2003), whereas
basal human TLR4 expression is regulated by interferon consen-
sus-binding protein (ICSBP) (Rehli et al., 2000), which is the IRF
with the highest sequence similarity to vIRF1. On the other
hand, vGPCR activates several signaling pathways (reviewed in
Cannon [2007]), none of which are directly associated with nega-
tive regulation of TLR4. We therefore investigated the mechanism
by which vGPCR causes suppression of TLR4 expression. ThisCell Hostwas addressed by determining TLR4 expression after treating
vGPCR-expressing LEC with chemical inhibitors of pathways
that are activated by this gene, such as the NF-kB, phosphatidy-
linositol-3-kinase (PI3K), ERK and Jun N-terminal kinase (JNK)
MAPK pathways, or those involved in TLR4 expression in other
cell types, such as the p38/MAPK pathway. We found that only
inhibitors of ERK phosphorylation were able to completely
reverse the observed TLR4 downregulation (Figure 7A) in a
dose-dependent manner (Figure 7B). To exclude any nonspecific
effects of the synthetic inhibitors we also showed that siRNA-
mediated silencing of ERK1 and ERK2 reversed the vGPCR-
mediated TLR4 suppression (Figure 7C), without affecting
expression of vGPCR (Figure S4A).
Next, we confirmed that ERK was phosphorylated in KLEC and
showed that inhibition of ERK activation partly restored TLR4
levels in KSHV-infected LEC (72 hr p.i.; Figure 7D). Although it
has been shown that inhibition of ERK activation before KSHV in-
fection inhibits viral gene expression (Sharma-Walia et al., 2005),
treatment of KLEC (72 hr p.i.) with ERK-phosphorylation inhibi-
tors did not affect viral gene expression (Figure S4B). Inhibitors
of PI3K, JNK, and p38 activation did not affect the KSHV-induced
TLR4 downregulation, showing that the effect of ERK-phosphor-
ylation inhibitors was not due to nonspecific inhibition of other& Microbe 4, 470–483, November 13, 2008 ª2008 Elsevier Inc. 475
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vGPCR to the observed TLR4 downregulation. The contribution
of the NF-kB pathway to TLR4 downregulation in KLEC was ex-
cluded, as NF-kB inhibitors did not affect the vGPCR-mediated
TLR4 downregulation, and vFLIP, the other major viral activator
of NF-kB, did not affect TLR4 expression (Table S2).
Following this, we tested the effect of ERK activation inhibitors
in the early TLR4 regulation by KSHV (6 hr p.i.), as it has been
Figure 4. Increased Susceptibility of LEC-TLR4A/G to KSHV Infection
(A) TLR4 expression in LEC-TLR4A/A (wild-type TLR4) and LEC-TLR4A/G (heterozygous mutation in TLR4 gene). Inserts show the corresponding pyrograms show-
ing a 50% loss of the fourth peak (corresponding to A) and 50% increase of the third peak (corresponding to a G) in the mutant cells. Bar graph shows mRNA levels
of TLR4 and TLR9 in LEC-TLR4A/A (gray bars) and LEC-TLR4A/G (black bars).
(B) mRNA levels of inflammatory cytokines and IFN-b in LEC-TLR4A/A (gray bars) and LEC-TLR4A/G (black bars) 6 hr poststimulation with LPS/sCD14. P values
indicate significant changes compared to LEC-TLR4A/A. mRNA levels are corrected for background transcription (in nonstimulated LEC).
(C) Representative dot plot of KSHV infected LEC-TLR4A/A and LEC-TLR4A/G. Numbers correspond to percentage of infected cells.
(D) KSHV gene expression in KLEC-TLR4A/A (gray bars) and KLEC-TLR4A/G (black bars) 72 hr p.i.P values indicate significant changes compared to KLEC-TLR4A/A.
In all panels, error bars represent standard deviation.476 Cell Host & Microbe 4, 470–483, November 13, 2008 ª2008 Elsevier Inc.
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TLR4 Role and Regulation in KSHV InfectionFigure 5. Association of TLR4 SNP with MCD
(A) TLR4 SNP map of 109 HIV-1-infected individuals. PN, patient number, DS, disease status (black, MCD and KS; dark gray, MCD; light gray, KS; white, other),
A/G, Asp299Gly, and C/T, Ile399Thr. Red and green boxes indicate presence of the corresponding SNP.
(B) Clinical characteristics and SNP incidence in the studied cohort. P values are calculated with Fischer Exact Probability Test.
(C) Box plot of plasma KSHV load at time of diagnosis in individuals with MCD (with or without KS) and KS only (available for 16 participants with KS only). Boxes
indicate the lower and upper quartiles, and the line indicates the median viral load for each group. The ends of the lines outside the boxes indicate minimum and
maximum loads, whereas circles represent outliers. Median and range of each group are also shown on top of each box. P value between the two groups is also
shown.shown that ERK activation is also caused by viral binding on the
surface of endothelial cells (Sharma-Walia et al., 2005). ERK
phosphorylation inhibitors and siRNA-mediated silencing of
ERK1 and ERK2 prior to infection reversed early TLR4 suppres-
sion in KLEC (6 hr p.i.; Figure 7D). Another possible mechanism
of TLR4 downregulation in endothelial cells during early stages
of infection, mediated by induction of reactive oxygen species
(Ishida et al., 2002), did not affect TLR4 expression in KLEC.
Inhibitors of ERK activation did not affect TLR9 mRNA levels in
KLEC (Figure S4C). This apparent specific effect of ERK activa-
tion on TLR4 in LEC could be explained by the fact that conserved
ETS binding sites are present in the TLR4 promoter, whereas the
human TLR9 promoter does not include any ETS (conserved or
nonconserved) sites (Figure S4D). Together, these data showed
that ERK phosphorylation due to viral binding mediates TLR4Cell Hostsuppression during the early stages of KSHV infection, whereas
ERK phosphorylation by vGPCR also contributes to TLR4
downregulation at 72 hr p.i.
DISCUSSION
Understanding the mechanisms of the host immune response
against viral infections and the strategies employed by viruses
to escape this response is crucial for designing new therapies
for infectious diseases. In the case of cancers caused by onco-
genic viruses, such as KSHV, current treatment regimes rely on
systemic cytotoxic therapy and immune system reconstitution
through antiretroviral therapy (ART), but take little advantage of
our current knowledge of KSHV immunobiology (Hansen et al.,
2007). In this respect, revealing the role and mechanisms of& Microbe 4, 470–483, November 13, 2008 ª2008 Elsevier Inc. 477
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TLR4 Role and Regulation in KSHV InfectionFigure 6. vIRF1 and vGPCR Contribute to the Downregulation of TLR4
(A) TLR4 mRNA and surface expression (geometrical mean fluorescence) levels in LEC expressing increasing amounts of vIRF1 (shown as average number of
lentiviral copies per cell, cc) and empty lentiviral vector (pSIN). Levels normalized to LEC-pSIN.
(B) TLR4 mRNA and surface expression levels in LEC expressing pSIN, vIRF1, vGPCR, and vIRF1 and vGPCR.
(C) Fold mRNA TNF-a induction and TNF-a secreted levels in LEC-expressing vIRF1 and vGPCR (black bars) or pSIN (gray bars) after stimulation with LPS/sCD14
and fold mRNA TNF-a induction after stimulation with CpG DNA. P values between stimulated LEC-pSIN and LEC-vIRF1/vGPCR are shown. For all panels,
experiments were performed 72 hr p.i. In all panels, error bars represent standard deviation.478 Cell Host & Microbe 4, 470–483, November 13, 2008 ª2008 Elsevier Inc.
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TLR4 Role and Regulation in KSHV Infectionregulation of the TLR-mediated response to KSHV is essential, as
clinically approved agonists and antagonists of several TLRs are
available (Kanzler et al., 2007). In this study, we define a particular
TLR (TLR4), which mediates an innate response against KSHV.
To our knowledge, this is the first report that implicates TLR4 in
immune responses against human herpesviruses.
TLR4 mediates antiviral immunity through induction of an
interferon antiviral gene expression program and production of
inflammatory cytokines. Its antiviral activity has been demon-
strated mainly against RNA viruses such as RSV and hepatitis
C virus (Kurt-Jones et al., 2000; Machida et al., 2006). We extend
the antiviral role of TLR4 to the family of human herpesviruses by
demonstrating that cells with reduced (siRNA silencing) or no
(knockout mice) TLR4 expression display an impaired immune
response during primary KSHV infection and increased viral
gene expression (Figure 2). Our findings also suggest that this
antiviral activity is due to direct binding between TLR4 and
a KSHV envelope glycoprotein, such as glycoprotein B or K8.1
(Figure 2). Importantly, although our data were obtained using
endothelial cells, it is likely that TLR4 also plays a role in innate
immunity during KSHV infection of B lymphocytes as these cells
express functional TLR4, and they are responsive to TLR4
ligands (Peng, 2005).
The only other virus, which has been shown to induce innate
immunity by direct interaction with TLR4 is RSV (Kurt-Jones
et al., 2000). In the context of RSV infection, the Asp299Gly and
Ile399Thr TLR4 mutations have been associated with severity
of RSV-induced bronchiolitis (Tal et al., 2004). It has been sug-
gested that these mutations affect TLR4 function by impairing
transport of the receptor to the cell membrane (Tulic et al.,
2007) and that the Asp299Gly SNP is associated with a proinflam-
matory phenotype (Ferwerda et al., 2007). In our study we
observed that LEC heterozygous for the Asp299Gly mutation
are more susceptible to KSHV infection (Figure 4), and we show
an association of the Asp299Gly SNP among HIV-1-infected indi-
viduals with MCD (Figure 5), a lymphoproliferation associated
with high KSHV load (Boivin et al., 2002; Oksenhendler et al.,
2000). Interestingly, our data suggest that this association with
MCD may be due to a combination of the impaired interferon
response and a proinflammatory phenotype of cells carrying
the Asp299Gly allele. Such a proinflammatory environment is
strongly associated with increased KSHV gene expression dur-
ing primary KSHV infection in vitro (Sadagopan et al., 2007) and
specifically MCD development in vivo (Oksenhendler et al.,
2000). Further larger prospective studies should evaluate these
findings and the association of these SNPs with KSHV-associ-
ated malignancies in other geographical and/or HIV-1-negative
cohorts. However, the results presented here provide the first
crucial insight into the role of TLR4 in controlling KSHV infection
in humans and identify the first genetic factor that could be asso-
ciated with MCD development.
Our results reveal KSHV as the first virus, which targets TLR4
expression as an immune evasion mechanism. Interestingly, it
has been reported that TLR4 is not expressed in the KS biopsy-
derived SLK endothelial cell line (Livengood et al., 2007). How-
ever, SLK cells have no detectable KSHV episome or viral gene
expression; therefore, the lack of TLR4 expression in this cell
line is unlikely to be associated with KSHV. Moreover, TLR4 is
a mediator of an innate response, and its regulation by the virusCell Host &should be rapid and occur during primary infection and lytic
replication when new cells are about to be infected. Importantly,
the maintenance of KSHV latency relies on this de novo infection
of cells (Grundhoff and Ganem, 2004). Consistent with the above,
in our primary infection model we observe a rapid and dramatic
drop of TLR4 expression in infected endothelial cells (Figure 1).
Of note immune evasion mechanisms employed by herpesvi-
ruses have evolved to delay immune responses allowing estab-
lishment of latency, rather than to completely escape immune
surveillance. Thus, it is not surprising that cells lacking TLR4
are more susceptible to infection by KSHV (Figure 2) despite
the fact that KSHV has evolved mechanisms to downregulate
TLR4. Furthermore, we excluded the possibility that this early
downregulation is a result of the previously reported mRNA shut-
off caused during the early stages of infection (Glaunsinger and
Ganem, 2004) by showing that TLR9 mRNA levels are not
affected by infection (Figure 1). We used TLR9 as control because
it is the TLR typically associated with responses to DNA viruses
(Akira et al., 2006), including the related murine gammaherpesvi-
rus-68 (Guggemoos et al., 2008). Our data do not exclude
that TLR9 could be regulated by KSHV at the posttranscriptional
level.
We show that ERK activation due to the activity of vGPCR
or KSHV structural proteins, such as K8.1 or glycoprotein B
(Sharma-Walia et al., 2005), plays a key role in the TLR4 down-
regulation in endothelial cells. Interestingly, it has been reported
that in murine dendritic cells ERK activation leads to TLR4 upre-
gulation (An et al., 2002), which suggests that TLR4 regulation is
cell-type specific. Moreover, we speculate that TLR4 regulation
through ERK activation in KLEC may be part of a more complex
signaling network involving the simultaneous activation of other
signaling cascades including crosstalk between different arms
of the MAPK signaling.
We identify two lytic KSHV genes, vIRF1 and vGPCR, that
contribute to TLR4 transcriptional repression in endothelial cells.
Our results demonstrate that vIRF1 and vGPCR lead to TLR4
downregulation through two independent mechanisms. vIRF1
is a known viral inhibitor of IRF-mediated transcription (Coscoy,
2007; Moore and Chang, 2003), with high homology to the cellu-
lar ICSBP, a transcription factor necessary for basal TLR4 ex-
pression (Rehli et al., 2000). We have previously shown that there
is background IRF-mediated transcription in LEC even in the ab-
sence of interferon (Lagos et al., 2007), which could explain the
effect of vIRF1 on TLR4 transcription. On the other hand, we
show that vGPCR-mediated TLR4 suppression occurs by way
of ERK activation (Figure 6). Of note, among the three main
MAPK pathways, p38 is mainly and positively associated with
TLR4 transcription, as the TLR4 gene has a PU.1 element in its
promoter.
The driving force in the evolution of herpesviruses is the estab-
lishment of latency in the host. This strongly depends on efficient
escape from the immune system, mainly during primary infection
and lytic replication. Our data reveal that evasion of TLR4-medi-
ated response is one such target for KSHV, and we show that
one of the mechanisms that the virus employs to escape this re-
sponse involves suppression of TLR4 expression. As we show
that TLR4 simulation impedes KSHV gene expression (Figure 3),
our findings suggest the potential of TLR4 agonists in KSHV-
related neoplasm prevention or treatment. Activation of TLR4Microbe 4, 470–483, November 13, 2008 ª2008 Elsevier Inc. 479
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TLR4 Role and Regulation in KSHV InfectionFigure 7. ERK Activation Contributes to TLR4 Downregulation in KLEC
(A) TLR4 mRNA levels in LEC-pSIN (black bar) and LEC-expressing vGPCR (gray bars) after treatment with the chemical inhibitors LY294002 (LY), BAY11-7082
(BAY), SB202190 (SB), JNK inhibitor II (JNK), PD98059 (PD), and UO126 (UO). Controls were treated with 0.1% DMSO.
(B) TLR4 mRNA levels in LEC-pSIN (black bar) and LEC-vGPCR (gray bars) after treatment with DMSO, 1 mM and 10 mM of UO126. Inset shows protein levels of
phosphorylated and total ERK in LEC-pSIN and LEC-vGPCR. For (A) and (B), levels are normalized to LEC-pSIN/0.1% DMSO.
(C) TLR4 expression in LEC-pSIN (black bars) and LEC-vGPCR (72 hr p.i., gray bars). LEC were transfected with nontargeting siRNA (scramble) or siRNAs target-
ing ERK1 and ERK2 (siERK) 48 hr before infection with pSIN or vGPCR lentivirus. Inset shows levels of ERK1 (top band) and ERK2 (bottom band) in scramble and
siERK LEC (48 hr posttransfection). SignificantP values between LEC-pSIN and LEC-vGPCR are shown. Bar graph shows levels of ERK1 and ERK2 in LEC-siERK
compared to LEC-scramble 48 hr posttransfection.480 Cell Host & Microbe 4, 470–483, November 13, 2008 ª2008 Elsevier Inc.
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TLR4 Role and Regulation in KSHV Infectioncould boost antigen presentation (Kanzler et al., 2007) and
potentiate cytotoxic therapy (Apetoh et al., 2007), but also exert
a direct antiviral effect. A future clinical study could be to inves-
tigate whether activation of TLR4 signaling with synthetic TLR4
agonists leads to reduced circulating KSHV load and therefore
could be used for the treatment of KSHV-related malignancies.
EXPERIMENTAL PROCEDURES
Animals and Cells
C57BL10/ScNJ (Jax mice number 003752) and C57BL10/ScSnJ mice (wild-
type for the Il12rb gene; Jax mice number 000476) were purchased from
Jackson Laboratory. Thioglycollate-induced peritoneal macrophages were
grown in Dulbecco’s modified Eagle’s medium (GIBCO), supplemented with
10% FCS. LEC were grown as described (Lagos et al., 2007). All experiments
were performed before passage 5. TLR4 signaling in LEC was activated with
1 mg/ml sCD14 and 100 ng/ml LPS for 6 hr. Under these conditions, LPS treat-
ment did not cause any apoptosis in LEC (tested with the MTT assay; not
shown). TLR9 signaling was activated by incubation of LEC with 5 mg/ml of
CpG type A, B, and C (ODN2336, ODN10103, ODN2395; Coley Pharma) for
16 hr. BCBL1-1C and 293T cells were grown as previously described (Lagos
et al., 2007).
KSHV Production and Infection of LEC
KSHV was produced and LEC were infected as previously described (Lagos
et al., 2007). KSHV was inactivated by UV irradiation for 30 min in a Stratalinker
2400 (Stratagene). LANA mRNA (by qRTPCR) was undetectable in LEC treated
with UV-inactivated KSHV 48 hr p.i. GFP expression in KLEC was used as
a surrogate marker of infection and infections typically resulted in 25%–40%
GFP-expressing KLEC (72 hr p.i.). KSHV infection of mouse macrophages
was detected by qRTPCR.
GEM Analysis
GEM profiles of six pairs of LEC and KLEC (3 days p.i.) were obtained and
analyzed as described (Lagos et al., 2007), using Affymetrix hg-u133+2
GeneChips. The GEM data are available in the ArrayExpress database (acces-
sion number E-MEXP-561).
Antibodies
Surface expression of proteins was assessed by flow cytometry (FACSCalibur,
Becton Dickinson). We used RPE labeled antibodies against human TLR4
(Santa Cruz), ICAM1 (PharMingen), and the corresponding isotype controls.
Analyses were done after gating live cells. The levels of ERK activation were de-
termined by western blot analysis using antibodies specific for phoshorylated
ERK1/2 (Cell Signaling Technology, Inc.) and total ERK1/2 (Upstate) as
described (Vart et al., 2007). Levels of phosphorylated and total IRAK1 were
determined using antibodies from Cell Signaling Technology, Inc. A neutralizing
antibody against the human IFNaRII was obtained from Merck.
Participants and TLR4 SNP Analysis
Blood samples were collected from HIV-1-infected individuals attending the St.
Stephen’s Centre at the Chelsea and Westminster Hospital. Sample collection,
preparation, and DNA extraction was carried out under ethical approval of the
Riverside Research Ethics Committee, and all participants gave informed con-
sent. Genomic DNA was extracted from 53 106 peripheral blood mononuclearCell Hoscells using the Nucleon Genomic DNA Extraction Kit (Tepnel Life Sciences) ac-
cording to the manufacturer’s instructions. DNA was resuspended in RNase/
DNase free water (Sigma) to a final concentration of 50 ng/ml and stored at
20C until required. TLR4 SNPs were assessed by pyrosequencing (Biotage,
UK). Primer sequences were designed using Pyrosequencing Assay Design
Software (Biotage) and were as follows: Forward PCR primer GACGATTAGCA
TACTTAGACTACTACCTC, reverse biotinylated PCR primer AGCCCAAGAA
GTTTGAACTCAT, Asp299Gly sequencing primer ATACTTAGACTACTACC
TCG, and Ile399Thr sequencing primer CAAAGTGATTTTGGGAC. The biotin-
labeled PCR products were purified with Steptavidin TM Sepharose Beads
(GE Healthcare) using the Pyrosequencing Preparation Station (Biotage) and
annealed to the sequencing primer at 80C for 2 min. The samples were then
run according to the instrument (PyroMarkTMMD) parameters.
Lentiviral Expression of KSHV Genes
KSHV genes were cloned from the BC3 and BC1 PEL cell lines and were
expressed using a modified pSIN-MCS lentiviral vector as described (Vart
et al., 2007). The number of lentiviral copies per cell was determined by
qPCR and viral gene expression was confirmed by RT-PCR. All experiments
shown were performed 3 days postlentivirus infection.
qRTPCR and qPCR
Genomic DNA and total RNA were extracted using the QIAamp DNA mini and
RNEasy mini kits, respectively (both from QIAGEN). TLR4, TLR9, TNF-a, IL1-b,
IL-6, LANA, ORF50, vIRF-1, vGPCR, and ORF26 mRNA levels were quantified
by qRTPCR using the SYBR Green Master Mix (Applied Biosystems, ABI Prism
7700). Optimized forward and reverse primers for these genes and GAPDH
(house-keeping reference gene) were used at final concentration of 300 nM.
For ERK1, ERK2, and IFN-b qRTPCR, commercially available primers were
used (Applied Biosytems). Cell-associated and plasma KSHV loads were
determined by qPCR as described (Bourboulia et al., 2004).
TNF-a ELISA
TNF-a levels in supernatants from LPS stimulated LEC were determined using
a commercially available ELISA (R&D Systems). TNF-a was not detectable in
supernatants of nonstimulated cells.
RNA Interference
LEC were seeded in 6-well plates 1 day prior to transfection with ERK1-, ERK2-,
or TLR4-targeting or nontargeting (scramble) siRNA (OnTargetPlus SmartPool
from Dharmacon). The concentration of siRNA was 100 nM, and cells were
transfected using oligofectamine reagent (Invitrogen). Cells were infected
with KSHV 48 hr post siRNA transfection.
Pharmacologic Inhibitions
We used the chemical inhibitors BAY11-7082 (NF-kB inhibitor, 5 mM), JNK
inhibitor II (25 mM), SB202190 (p38/MAPK inhibitor, 10 mM), PD98059 (MEK
inhibitor, 10 mM), UO126 (MEK inhibitor, 10 mM), and LY294002 (PI3K inhibitor,
5 mM), all from Calbiochem. For LEC and KLEC at 72 hr p.i., and LEC infected
with lentivirus, the inhibitors were added to the cells for 6 hr, apart from BAY11-
7082 and LY294002, which were added for 2 hr and 4 hr, respectively. For LEC
and KLEC at 6 hr p.i., all inhibitors were added to the cells for 2 hr prior to
infection and removed during infection. Polymyxin B, N-acetylcysteine, and
ascorbic acid (all from Sigma) were used at 10 mg/ml, 2.5 mM, and 1 mM con-
centrations, respectively. Cell viability was not affected by any of the inhibitors
in the above conditions (not shown).(D) TLR4 expression in LEC (black bars) and KLEC (72 hr p.i., gray bars) after treatment of cells with DMSO, SB202190, JNK inhibitor II, UO126, PD98059, or
LY294002. P values indicate statistical significance of changes between KLEC-DMSO and KLEC-UO or KLEC-PD. Inset shows protein levels of phosphorylated
and total ERK in LEC-DMSO, KLEC-DMSO, and KLEC treated with UO126 MEK-inhibitor. P values indicate statistically significant changes between LEC-DMSO
and KLEC samples.
(E) TLR4 expression in LEC (black bars) and KLEC (6 hr p.i., gray bars) after treatment with DMSO (control for chemical inhibitors) or media (control for anti-
oxidants), N-acetyl-cysteine and ascorbic acid (anti-oxidants), LY294002, and UO126. TLR9 mRNA levels in LEC-DMSO, KLEC-DMSO, and KLEC treated
with UO126 (6 hr p.i.).
(F) TLR4 expression in LEC (black bars) and KLEC (6 hr p.i., gray bars). Cells were transfected with nontargeting siRNA (scramble) or siRNAs targeting ERK1 and
ERK2 (siERK) 48 hr before infection with KSHV. P values indicate significant changes between LEC and KLEC. In all panels, error bars represent standard
deviation.t & Microbe 4, 470–483, November 13, 2008 ª2008 Elsevier Inc. 481
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TLR4 Role and Regulation in KSHV InfectionTLR Promoter Analysis
The promoters (1 kB upstream the transcription start site) of human TLR4 and
TLR9 were analyzed using DiAlign TF with incorporated MatInspector
software.
Statistical Analysis
All experiments were performed in four to six independent replicates, and error
bars correspond to standard deviation from the mean. Statistical significance
(P values) was determined with a two-sided unpaired Student’s t test. Statis-
tical analysis of GEM was performed as described using a moderated t statistic
and a false discovery rate correction (Lagos et al., 2007; Wang et al., 2004).
Statistical significance of the frequency of the TLR4 SNPs among HIV-1-
infected individuals was determined using the Fischer Exact Probability Test.
SUPPLEMENTAL DATA
Supplemental Data include four figures and two tables and can be
found online at http://www.cell.com/cellhostandmicrobe/supplemental/
S1931-3128(08)00331-4.
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